EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group

Hannah B Maier, Anton Borchert, Alexandra Neyazi, Nicole Moschny, Rasmus Schülke, Gabriel L Bundies, Thorsten Folsche, Anastasia Gaspert, Johanna Seifert, Stefan Bleich, Maike Scherf-Clavel, Stefan Unterecker und 3 weitere

Pharmacopsychiatry · 01.07.2024 · 57 (04) · 191-203

DOI: 10.1055/a-2292-1438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.07.2024. Verfasst von Hannah B Maier und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany. Hauptthemen laut MEDLINE: Antidepressive Agents, Comorbidity, Depressive Disorder, Treatment-Resistant, Disease Susceptibility. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approximately 15–25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidities or (pseudo-)resistance to antidepressant drugs (ADs). Polymorphisms of the cytochrome P450 (CYP) enzymes 2D6 and 2C19, which play a major role in the metabolism of ADs, may contribute to resistance to ADs. Patients with DTD might benefit from electroconvulsive therapy (ECT).

Methods

We enrolled 109 patients with DTD and 29 untreated depressed controls (UDC). We assessed risk phenotypes, comorbidities, and treatment, including ECT. We also performed pharmacokinetic analyses of CYP2D6 and CYP2C19.

Results

DTD patients significantly more often suffered from comorbid psychiatric diseases, especially ICD-10: F40-F48 (DTD:40.4%, UDC:17.2%, OR 11.87, p=0.011) than UDC patients. DTD patients receiving ECT were more likely to achieve remission (37.7% vs. 11.8%, OR=3.96, p=0.023). Treatment with ADs did not differ between remitters and non-remitters. No significant differences were observed in the distribution of CYP2D6 and CYP2C19 variants between both groups.

Conclusion

Patients with DTD appear to experience comorbid neurotic stress and somatoform disorders (ICD-10: F40 – F48) more frequently. Therefore, a comprehensive differential diagnosis is crucial when patients do not respond sufficiently to antidepressant medication. Genotyping CYP2D6 and CYP2C19 should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsComorbidityDepressive Disorder, Treatment-ResistantDisease SusceptibilityElectroconvulsive TherapyPhenotypeFemaleHumansMaleCase-Control StudiesCohort StudiesCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Mental DisordersPharmacogenomic TestingAdolescentYoung AdultAdultMiddle AgedAgedTreatment Outcome

Substanzen

Antidepressive AgentsCYP2C19 protein, humanCYP2D6 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6

Autor:innen und Institutionen

  • Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
  • Department of Psychiatry and Psychotherapy, Otto von Guericke University Magdeburg, Germany.
  • Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany.

Zitieren

APA

Maier, H. B., Borchert, A., Neyazi, A., Moschny, N., Schülke, R., Bundies, G. L., Folsche, T., Gaspert, A., Seifert, J., Bleich, S., Scherf-Clavel, M., Unterecker, S., Deckert, J., Frieling, H., & Weber, H. (2024). Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group. Pharmacopsychiatry, 57(04), 191-203. https://doi.org/10.1055/a-2292-1438

Vancouver

Maier HB, Borchert A, Neyazi A, Moschny N, Schülke R, Bundies GL, et al. Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group. Pharmacopsychiatry. 2024;57(04):191-203. doi:10.1055/a-2292-1438

BibTeX
@article{Maier2024,
  author = {Maier, Hannah B and Borchert, Anton and Neyazi, Alexandra and Moschny, Nicole and Schülke, Rasmus and Bundies, Gabriel L and Folsche, Thorsten and Gaspert, Anastasia and Seifert, Johanna and Bleich, Stefan and Scherf-Clavel, Maike and Unterecker, Stefan and Deckert, Jürgen and Frieling, Helge and Weber, Heike},
  title = {Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group},
  journal = {Pharmacopsychiatry},
  year = {2024},
  volume = {57},
  number = {04},
  pages = {191--203},
  doi = {10.1055/a-2292-1438}
}
Kostenlos starten →